Journal
DEVELOPMENTAL NEUROSCIENCE
Volume 43, Issue 3-4, Pages 241-246Publisher
KARGER
DOI: 10.1159/000516143
Keywords
Epilepsy; Alternative splicing; Poison exons; Antisense oligonucleotide; Genetics
Categories
Funding
- Dravet Syndrome Foundation Research Grant
Ask authors/readers for more resources
Developmental and epileptic encephalopathies (DEEs) are a subset of neurodevelopmental disorders characterized by refractory epilepsy, intellectual disability, and autism spectrum disorder. Most cases have a genetic basis, with PEs playing an important role in DEEs. Targeting PEs has been shown to improve the condition of patients with DEEs.
Developmental and epileptic encephalopathies (DEEs) describe a subset of neurodevelopmental disorders categorized by refractory epilepsy that is often associated with intellectual disability and autism spectrum disorder. The majority of DEEs are now known to have a genetic basis with de novo coding variants accounting for the majority of cases. More recently, a small number of individuals have been identified with intronic SCN1A variants that result in alternative splicing events that lead to ectopic inclusion of poison exons (PEs). PEs are short highly conserved exons that contain a premature truncation codon, and when spliced into the transcript, lead to premature truncation and subsequent degradation by nonsense-mediated decay. The reason for the inclusion/exclusion of these PEs is not entirely clear, but research suggests an autoregulatory role in gene expression and protein abundance. This is seen in proteins such as RNA-binding proteins and serine/arginine-rich proteins. Recent studies have focused on targeting these PEs as a method for therapeutic intervention. Targeting PEs using antisense oligonucleotides (ASOs) has shown to be effective in modulating alternative splicing events by decreasing the amount of transcripts harboring PEs, thus increasing the abundance of full-length transcripts and thereby the amount of protein in haploinsufficient genes implicated in DEE. In the age of personalized medicine, cellular and animal models of the genetic epilepsies have become essential in developing and testing novel precision therapeutics, including PE-targeting ASOs in a subset of DEEs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available